Home | Business News | Browse by Publication | M | M2 Presswire

Current Research on Thermogenesis Corp.

Article Excerpt
M2 PRESSWIRE-29 June 2007-Biotech News: Current Research on Thermogenesis Corp(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:29062007

Current Research on Thermogenesis Corp (NASDAQ:KOOL)

ThermoGenesis Corp. designs, manufactures, and markets automated blood processing systems and disposables that enable the manufacture, preservation, and delivery of personalized cell therapy and surgical wound care products for clinical use worldwide. In cell therapy, the initial configuration of its products automates the isolation, capture, and preservation of stem cells residing in the blood of the placenta and umbilical cord after a baby is born. These cells are used to treat patients for leukemia, lymphoma, and approximately 60 other life threatening genetic diseases. Its products include BioArchive System, an automated cryogenic system used in cell therapy to cryopreserve and archive cord blood stem cells for future transplant; AutoXpress System, an automated system and disposable intended for use in cell therapy to isolate and capture stem cells from cord blood; and CryoSeal Fibrin Sealant System, an automated system used to prepare an autologous hemostatic surgical sealant from a patient's own blood. The company's products also comprise Thrombin Processing Device, used to isolate activated thrombin from the...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!